Sinopharm Group (HKG:1099) reported a net profit attributable to the parent of 3.70 billion yuan for the first six months ended June 30, a 9.76% decline compared with the 4.10 billion yuan profit reported in the year-ago period, according to the company's interim report filed with the Hong Kong bourse Wednesday.
Earnings per share were 1.19 yuan per share, down from 1.32 yuan per share a year earlier.
Revenue of the pharmaceutical company fell to 294.73 billion yuan from 300.95 billion yuan in the prior-year period
Price (HKD): $17.98, Change: $+0.74, Percent Change: +4.29%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。